Cormorant Asset Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Cormorant Asset Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-30,000	Closed	-$2.81M	–	92
2016 Q1	$2.81M	Hold	30,000	–	–	0.42%	57
2015 Q4	$6.08M	Buy	+30,000	New	+$5.37M	0.73%	43
2015 Q2	–	Sell	-5,100	Closed	-$1.18M	–	86
2015 Q1	$1.18M	Sell	5,100 -900	-15%	-$218K	0.18%	59
2014 Q4	$1.38M	Buy	+6,000	New	+$1.29M	0.21%	57

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cormorant Asset Management's BLCM Position: Q2 2016 in Review

Cormorant Asset Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q2 2016, closing a stake of 30,000 shares — an estimated $2.81M sold.

Cormorant Asset Management first reported a position in BLCM in Q4 2014 and held it in 4 quarters. The position peaked at $6.08M in Q4 2015. 67 funds tracked by Wall St. Rank hold BLCM as of Q2 2016.

Cormorant Asset Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
Cormorant Asset Management sold 30,000 Bellicum Pharmaceuticals, Inc. shares in Q2 2016, an estimated $2.81M.
Cormorant Asset Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q4 2014 and held it in 4 quarters.
Cormorant Asset Management's Bellicum Pharmaceuticals, Inc. position peaked at $6.08M in Q4 2015.
67 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q2 2016.

Based on Cormorant Asset Management's 13F filing for Q2 2016, filed 15 Aug 2016.